Skip to content
Lower risk Drug recall · FDA · Published October 7, 2019

Mylan Rifampin Injection Recall: Possible Reduced Effectiveness Due to Discoloration

Mylan recalls Rifampin injections for possible reduced effectiveness due to discoloration from impurities. Affected lots manufactured in 2019-2020.

🇺🇸 FDA recall #D-0139-2020DrugMylan ›
Take action

Contact the company

Recalling firmMylan Laboratories Limited (Sterile Products Division)Opp. Iim-B, Bilekahalli , Bannerghatta Road · Bangalore, India
✎ GovInfoNow plain-language explainer

Mylan is recalling Rifampin injections that may have discoloration from impurities, which could make the medicine less effective. This affects patients using the medication as prescribed by their doctor. Read more at govinfonow.com/recall/37869-mylan-rifampin-injection-recall-possible-reduced-effectiveness-due-to-discoloration.

Source Summary by GovInfoNow · govinfonow.com/recall/37869-mylan-rifampin-injection-recall-possible-reduced-effectiveness-due-to-discoloration · Updated October 5, 2026 · FDA enforcement record: FDA #D-0139-2020

Cite this page

“Mylan Rifampin Injection Recall: Possible Reduced Effectiveness Due to Discoloration.” GovInfoNow, updated October 5, 2026. https://govinfonow.com/recall/37869-mylan-rifampin-injection-recall-possible-reduced-effectiveness-due-to-discoloration. Based on FDA recall #D-0139-2020 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0139-2020%22&limit=1).

The Food and Drug Administration announced on Oct. 7, 2019, that Mylan Laboratories Limited voluntarily recalled Rifampin for Injection due to failed impurity specifications. The agency stated the recall addresses discoloration from elevated unknown impurities that could decrease the product's effectiveness.

How to tell if you have it

  • Brand: Mylan
  • Product: Rifampin for Injection, USP, 600 mg/vial
  • NDC: 67457-445-60
  • Lot codes: 7008334 (Exp April 2020), 7008417 (Exp Oct 2020)
  • Quantity: 19,165 vials

The hazard

The recall addresses discoloration caused by elevated unknown impurity results. According to the FDA, this defect could decrease the effectiveness of the product.

Context

GovInfoNow's records show other recent recalls include Mylan Mycophenolate Mofetil Injection Recall (2026-07-02) and Mylan Mycophenolate Mofetil Injections: Failed Dissolution Specifications (2026-08-26). Additional similar product recalls listed by GovInfoNow include Mylan Prasugrel Tablets Recall (2026-08-17).

How to tell if you have this one

Check for discoloration in the vial. The product was manufactured for Mylan Institutional LLC in Rockford, IL with specific lot numbers (7008334, 7008417) and expiration dates (April 2020, October 2020).

  • Brand
    Mylan
  • Category
    Drug
Based on the official FDA remedy

What to do — step by step

  1. Check for Discoloration

    Look for discoloration in the vial before using the medication.

Where it went and when

Where it was distributed

Distributed nationwide.

Alaska: yesAKMaine: yesMEVermont: yesVTNew Hampshire: yesNHWashington: yesWAIdaho: yesIDMontana: yesMTNorth Dakota: yesNDMinnesota: yesMNIllinois: yesILWisconsin: yesWIMichigan: yesMINew York: yesNYRhode Island: yesRIMassachusetts: yesMAOregon: yesORNevada: yesNVWyoming: yesWYSouth Dakota: yesSDIowa: yesIAIndiana: yesINOhio: yesOHPennsylvania: yesPANew Jersey: yesNJConnecticut: yesCTCalifornia: yesCAUtah: yesUTColorado: yesCONebraska: yesNEMissouri: yesMOKentucky: yesKYWest Virginia: yesWVVirginia: yesVAMaryland: yesMDDelaware: yesDEArizona: yesAZNew Mexico: yesNMKansas: yesKSArkansas: yesARTennessee: yesTNNorth Carolina: yesNCSouth Carolina: yesSCDistrict of Columbia: yesDCOklahoma: yesOKLouisiana: yesLAMississippi: yesMSAlabama: yesALGeorgia: yesGAHawaii: yesHITexas: yesTXFlorida: yesFL

FDA distribution: “Nationwide in the USA” States read from FDA’s own wording; “not listed” means the notice does not name it.

Distributed nationwide.

Recall timeline

FDA terminated this recall 3.4 years after the firm started it.

1. Firm started the recall: Oct 7, 201912. FDA classified it Class II: Oct 10, 201923. Published in FDA’s Enforcement Report: Oct 16, 201934. FDA terminated the recall: Mar 9, 2023420192023
  1. Firm started the recall
  2. FDA classified it Class II
  3. Published in FDA’s Enforcement Report
  4. FDA terminated the recall

Dates from the agency record only; steps without a date are left out.

Similar recalls

Latest drug recalls

Keep exploring

Where this comes from

The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.

  • Official source: FDA Recall #D-0139-2020 (October 7, 2019) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0139-2020 to see it in context.
  • Plain-language summary written by qwen3:4b on October 5, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
  • GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.
GovInfoNow is an independent guide. We are not FDA or any government agency. Always confirm details with the official recall.Data: CPSC · FDA · NHTSA · USDA